169 completed, 43 terminated, 12 recruiting, 12 unknown. 155 Phase 2, 83 Phase 1, 20 Phase 3, 10 Not applicable, 6 Phase 4.
Follow this drug Literature Review of pazopanib trials Research Report on pazopanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas Pazopanib, Trabectedin, Ipilimumab - Soft Tissue Sarcomas | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-06-12 | 2026-08-06 |
| A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma IBR854, Pazopanib - Renal Cell Carcinoma (RCC) | Phase 2 | Recruiting | Imbioray (Hangzhou) Biomedicine Co., Ltd. | 30 | 2025-09-08 | 2026-07-02 |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice - Metastatic Sarcoma, Recurrent Sarcoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 20 | 2025-02-25 | 2026-08-11 |
| Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents pazopanib, TGI chemotherapy, CIV chemotherapy - Rhabdomyosarcoma, Recurrent, Refractory | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 38 | 2025-02-01 | 2025-02-10 |
| Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) Pazopanib Oral Tablet, Palbociclib - Solid Tumor, Adult, Next-generation Sequencing | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 65 | 2024-11-27 | 2025-03-26 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion Olaparib tablet, Temozolomide capsule, Anlotinib - Solid Tumor, Precision Medicine | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 300 | 2024-11-01 | 2024-12-18 |
| Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) Stereotactic body radiotherapy (SBRT), axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib - Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic | Phase 3 | Recruiting | Sun Yat-sen University | 252 | 2024-09-18 | 2026-01-15 |
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) INT230-6, Eribulin, Trabectedin - Sarcoma,Soft Tissue | Phase 3 | Recruiting | Intensity Therapeutics, Inc. | 333 | 2024-06-28 | 2026-08-11 |
| OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Olaparib, Lenvatinib, Sunitinib - Renal Cell Carcinoma, Ovarian Carcinoma | Phase 4 | Unknown | University Medical Center Groningen | 30 | 2024-05-01 | 2023-11-29 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma pembrolizumab, pazopanib - Soft Tissue Sarcoma | Phase 2 | Recruiting | Yonsei University | 116 | 2024-03-01 | 2025-07-16 |
| Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia Pazopanib - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 1 / Phase 2 | Unknown | Cure HHT | 30 | 2023-07-01 | 2022-09-08 |
| Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Pazopanib, Placebo oral capsule - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 / Phase 3 | Active not recruiting | Cure HHT | 70 | 2023-05-08 | 2026-03-19 |
| Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2023-03-30 | 2026-10-01 |
| Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma sunitinib or pazopanib, PD-1 inhibitor combined with axitinib - Metastatic Renal Cell Carcinoma | Not applicable | Unknown | RenJi Hospital | 500 | 2022-08-01 | 2023-04-18 |
| Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults Spartalizumab in Pediatric cohort, Low-dose Pazopanib in Pediatric Cohort, Spartalizumab in Adult cohort - Refractory or Recurrent Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | University Hospital, Bordeaux | 80 | 2022-05-17 | 2026-01-15 |
| HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas Pazopanib, HDM201 - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Centre Leon Berard | 47 | 2022-04-15 | 2026-06-22 |
| Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient] - Sarcoma | Phase 3 | Unknown | Centre Leon Berard | 96 | 2021-03-30 | 2023-08-30 |
| Pazopanib Vs. Pazopanib Plus Gemcitabine Pazopanib plus Gemcitabine, Pazopanib - Leiomyosarcoma or Carcinosarcoma | Phase 2 | Active not recruiting | North Eastern German Society of Gynaecological Oncology | 58 | 2019-10-16 | 2024-11-15 |
| A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma Durvalumab, pazopanib - Sarcoma | Phase 2 | Completed | Yonsei University | 46 | 2019-04-10 | 2023-06-12 |
Showing 20 of 258. Sign in to see all of them.
Carcinoma, Renal Cell (65) · Sarcoma (40) · Neoplasm Metastasis (22) · Neoplasms (20) · Breast Neoplasms (17) · Ovarian Neoplasms (17) · Carcinoma, Non-Small-Cell Lung (15) · Leiomyosarcoma (8) · Kidney Neoplasms (7) · Recurrence (7) · Clear-cell metastatic renal cell carcinoma (6) · Fallopian Tube Neoplasms (6) · Glioblastoma (6) · Hemangiosarcoma (6) · Liposarcoma (6)
GlaxoSmithKline (47) · National Cancer Institute (NCI) (26) · M.D. Anderson Cancer Center (10) · Novartis Pharmaceuticals (10) · Samsung Medical Center (8) · Centre Leon Berard (5) · Spanish Oncology Genito-Urinary Group (4) · Washington University School of Medicine (4) · Dana-Farber Cancer Institute (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · Heidelberg University (3) · Northwestern University (3) · SCRI Development Innovations, LLC (3) · Tracon Pharmaceuticals Inc. (3) · UNICANCER (3)
United States (143) · France (36) · Germany (33) · United Kingdom (27) · South Korea (25) · Spain (25) · Italy (22) · China (19) · Canada (18) · Australia (14) · Netherlands (14) · Belgium (12) · Taiwan (11) · Austria (10) · Singapore (9)
Charles Theuer, MD (3) · Amado Zurita, MD (2) · Giuseppe Procopio, MD (2) · Keith C Bible (2) · Ki Woong Sung, MD, PhD (2) · Mark Pomerantz, MD (2) · Peter Hohenberger, MD (2) · Aaron R Weiss (1) · Ajjai Alva, M.D. (1) · Alexander Mustea, Prof. Dr. med. (1)
PMID 37185961, PMID 37146227, PMID 23054212, PMID 26702763, PMID 23964934, PMID 24113783, PMID 24504442, PMID 24687826, PMID 26457466, PMID 26588236, PMID 26685869, PMID 27101285, PMID 29788981, PMID 31401903, PMID 32171288, PMID 12890838, PMID 14555767, PMID 14685170, PMID 16127434, PMID 18230058, PMID 18650835, PMID 18980965, PMID 19762372, PMID 19844230, PMID 20100962, PMID 20103651, PMID 20200024, PMID 20215520, PMID 20606083, PMID 20616894, PMID 20851682, PMID 20952508, PMID 21346036, PMID 22006050, PMID 22014006, PMID 22084371, PMID 22330762, PMID 22434312, PMID 22759480, PMID 23233252, PMID 23333114, PMID 23456563, PMID 23636448, PMID 23665131, PMID 23698253, PMID 23857966, PMID 23989950, PMID 24308791, PMID 24399786, PMID 24464355
P30CA015083 (5), N01CM62205 (4), 2009 (3), U10CA180821 (3), U10CA180830 (3), U10CA180868 (3), 2008 (2), 2017 (2), N01CM00099 (2), N01CM62203 (2), P30CA015704 (2), P30CA072720 (2), U10CA027469 (2), 2014 (1), 2015 (1)